Skip to content

Study · Case report or series · n = 1 · 2022

4 results

Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide.

Sawamura T, Karashima S, Ohmori A, Sawada K, Kometani M, Takeda Y, Yoneda T

Medicina (Kaunas, Lithuania)14 Feb 2022Cited by 1 (Europe PMC)

PMID35208612 (opens in a new tab)PMCIDPMC8876704 (opens in a new tab)DOI10.3390/medicina58020289 (opens in a new tab)PepBankPUB-35208612
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome is characterized by symmetrical polyarthritis and limb pitting edema. Although the detailed mechanisms of this syndrome have not been clearly understood, some agents including dipeptidyl peptidase-4 inhibitors have been reported to induce RS3PE syndrome. However, glucagon-like peptide-1 (GLP-1) analogues have not been reported to be associated with this syndrome. A 91-year-old woman was admitted to our hospital with complaints of severe polyarthritis and limb edema. She was diagnosed with RS3PE syndrome. Oral prednisolone improved her symptoms. However, her symptoms worsened after the administration of dulaglutide, with elevated serum inflammatory markers. Discontinuation of dulaglutide without additional treatment improved her symptoms and laboratory findings. This case might indicate the possibility of development and worsening of RS3PE syndrome caused after GLP-1 analogue.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a woman with RS3PE syndrome, symptoms worsened after dulaglutide administration.

    In plain wordsIn one woman with RS3PE syndrome, symptoms worsened after dulaglutide began.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseRS3PE symptoms after administration
    Study

    n = 1

    Comparator
    Before dulaglutide
    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, her symptoms worsened after the administration of dulaglutide, with elevated serum inflammatory markers.
    2 context sentences
    Summary · context
    A 91-year-old woman was admitted to our hospital with complaints of severe polyarthritis and limb edema.
    Summary · context
    She was diagnosed with RS3PE syndrome.
  2. 02HumanCase report or seriesSafety outcome

    In a woman with RS3PE syndrome, serum inflammatory markers were elevated after dulaglutide administration.

    In plain wordsIn one woman with RS3PE syndrome, blood inflammation markers rose after dulaglutide began.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseInflammatory markers after administration
    Study

    n = 1

    Comparator
    Before dulaglutide
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, her symptoms worsened after the administration of dulaglutide, with elevated serum inflammatory markers.
    2 context sentences
    Summary · context
    A 91-year-old woman was admitted to our hospital with complaints of severe polyarthritis and limb edema.
    Summary · context
    She was diagnosed with RS3PE syndrome.
  3. 03HumanCase report or seriesSafety outcome

    In a woman with RS3PE syndrome, symptoms improved after dulaglutide discontinuation without additional treatment.

    In plain wordsIn one woman, symptoms improved after dulaglutide stopped, without additional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseSymptoms after discontinuation
    Study

    n = 1

    Comparator
    During dulaglutide treatment
    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Discontinuation of dulaglutide without additional treatment improved her symptoms and laboratory findings.
    2 context sentences
    Summary · context
    A 91-year-old woman was admitted to our hospital with complaints of severe polyarthritis and limb edema.
    Summary · context
    She was diagnosed with RS3PE syndrome.
  4. 04HumanCase report or seriesSafety outcome

    In a woman with RS3PE syndrome, laboratory findings improved after dulaglutide discontinuation without additional treatment.

    In plain wordsIn one woman, laboratory results improved after dulaglutide stopped, without additional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedLaboratory findings after discontinuation
    Study

    n = 1

    Comparator
    During dulaglutide treatment
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Discontinuation of dulaglutide without additional treatment improved her symptoms and laboratory findings.
    2 context sentences
    Summary · context
    A 91-year-old woman was admitted to our hospital with complaints of severe polyarthritis and limb edema.
    Summary · context
    She was diagnosed with RS3PE syndrome.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.